LATEST UPDATES » Vol 24, No 12, December 2019 – Precision Medicine for Brain Tumours       » First Alzheimer's drug to be approved in 17 years holds promise for treatment       » Tencent make medical information readily available to the public       » United States FDA approves first China-made cancer drug       » Value-Based Healthcare: A Paradigm Shift for Better Patient Outcomes       » Precision Agriculture for Future Nutritional Needs      
Advent Access receives CE Mark certificate for pioneering av-GuardianTM vascular access system
The av-GuardianTM is the world’s first implant technology with the concept of establishing a “guardian guide-door” to facilitate dialysis needles to optimally access the dialysis vein without being in contact with the vein.

Receiving the CE Mark certificate indicates that av-GuardianTM conforms with health, safety, and environmental protection standards set by the European Union for a device to be distributed into the European Economic Area.

The technology is compatible with patients undergoing haemodialysis in various treatment settings whether in dialysis centres or at home, regardless of the types of dialysis machine used.

Providing reliable access to the dialysis vein, the arteriovenous fistula (AV fistula), remains one of the most stressful and challenging parts of haemodialysis. Moreover, during this procedure many complications can often arise due to poor needling, leading to inadequate dialysis or vascular access related hospitalizations.

Peh Ruey Feng, Chief Executive Officer and Founder of Advent Access, said: “Receiving CE Mark approval for av-GuardianTM is an important milestone in our mission to provide a more comfortable treatment for patients suffering long term end-stage kidney disease and to reduce the cost burden of maintenance dialysis. Our focus now is to work with high-quality manufacturing and distribution partners to realize the impact we can make in potentially changing the way haemodialysis patients receive treatment both in-centre or at home.”

av-GuardianTM technology was recently evaluated in a first-in-man study conducted at the Singapore General Hospital and National University Hospital of Singapore, with the support from the National Kidney Foundation. The study conducted was a non-randomized, prospective clinical trial to access the safety and clinical performance of av-GuardianTM. Results of the study showed av-GuardianTM met all safety and performance endpoints across 216 haemodialysis sessions in patients with native AV fistula. Achieving a 94 to 98 per cent success rate in access to the AV fistula, and 86 to 90 per cent success at first needle attempt.

Today, an estimated 2.5 million patients suffer from end-stage renal disease (ESRD) and it is estimated that this figure will more than double to 5.5 million patients worldwide by 2030. 89 per cent of ESRD patients rely on haemodialysis to sustain their lives until a kidney transplant is received. The haemodialysis market is valued at USD$71 billion in 2017 and is forecasted to be worth USD$99 billion by 2025.

Advent Access is focused on developing solutions to address the rising cost of operating in-centre haemodialysis and the limited scalability of dialysis centres when they reach maximum capacity.

Click here for the complete issue.

news Proteona awards grant to clinician-scientist for research in treatment selection of multiple myeloma
news Technology giant, Tencent Holdings Limited, promotes medical science and healthcare
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Marijuana as medicine — Legal marijuana will open up scientific research
Driven by curiosity
Career developments for researchers
What's cracking — Antibodies in ostrich eggs
Clinical trials — What's in a name?
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
Healthy Ageing — How Science is chipping in
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
Evaluating cost effectiveness of genomic profiling
Precision Medicine for Brain Tumours
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy